The dilemma of intellectual property rights for pharmaceuticals: The tension between ensuring access of the poor to medicines and committing to international agreements

Developing World Bioethics 3 (1):27–48 (2003)
  Copy   BIBTEX

Abstract

In this paper, we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally. Second, we explain how specific pharmaceutical policy tools can help developing states mitigate the worst effects of the TRIPS Agreement. Third, we put forward solutions that could be implemented by the World Bank to help overcome the divide between creating private incentives for research and development of innovative medicines and ensuring access of the poor to medicine. Fourth, we evaluate these solutions on the basis of utilitarian considerations and urge that equitable pricing is morally preferable to the other solutions.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 90,593

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Analytics

Added to PP
2009-01-28

Downloads
61 (#237,812)

6 months
3 (#445,838)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

References found in this work

No references found.

Add more references